Hyperforin acts as an angiogenesis inhibitor in vitro and in vivo

Planta Medica

Volumn 71, Issue 11, 2005, Pages 999-1004

  Schempp, Christoph M ^a   Kiss, Judit ^b   Kirkin, Vladimir ^c   Averbeck, Marco ^d   Simon Haarhaus, Birgit ^a   Kremer, Bernhard ^a   Termeer, Christian C ^a   Sleeman, Jonathan ^c   Simon, Jan C ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Angiogenesis; Apoptosis; CD31; Endothelial cells; Microvessels

Indexed keywords

ANGIOGENESIS INHIBITOR; CAMPTOTHECIN; CD31 ANTIGEN; HYPERFORIN; SOLVENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HYPERICUM PERFORATUM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STAINING; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BICYCLO COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; PHLOROGLUCINOL; RATS; RATS, WISTAR; TERPENES;

ANIMALIA; HYPERICUM PERFORATUM; RATTUS NORVEGICUS;

EID: 29144531292     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-871303     Document Type: Article

References (32)

1. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression - an overview and metaanalysis of randomized clinical trials. Br Med J 1996; 313: 253-8
2. Kaul R. Johanniskraut. Botanik, Inhaltsstoffe, Qualitätskontrolle, Pharmakologie, Toxikologie und Klinik. Stuttgart: Wiss Verlagsges; 2000.
3. Bystrov NS, Chernov BK, Dobrynin VN, Kolosov MN. The structure of hyperforin. Tetrahedron Lett 1975; 16: 2791-4
4. Maisenbacher P, Kovar KA. Analysis and stability of Hyperici oleum. Planta Med 1992; 58: 351-4
5. Gurevich AI, Dobrynin VN, Kolosov MN, Popravko SA, Ryabova ID, Chernov BK et al. Hyperforin, an antibiotic from Hypericum perforatum L. Antibiotiki 1971; 16: 510-3
6. Schempp CM, Pelz K, Wittmer A, Schöpf E, Simon JC. Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and Gram-positive bacteria. Lancet 1999; 353: 2129
7. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998; 31 (Suppl 1): 16-21
8. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002; 64: 1767-75
9. Schempp CM, Winghofer B, Lüdtke R, Simon-Haarhaus B, Schöpfe, Simon JC. Topical application of St. John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol 2000; 142: 979-84
10. Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 2002; 21: 1242-50
11. Hostanska K, Reichling J, Bommer S, Weber M, Sailer R. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 2003; 56: 121-32
12. Dona M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004; 64: 6225-32
13. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3: 505-9
14. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A. Angiogenesis as a target for tumor treatment. Oncology 2001; 54: 177-84
15. Liekens S, de Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70
16. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 1043-6
17. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 1996; 8: 60-5
18. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57
19. Detmar M. Tumor angiogenesis. J Invest Dermatol Symp Proc 2000; 5: 20-3
20. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-18
21. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1997; 9: 584-9
22. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401-7
23. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M et al. Effects of PTK787/ZK 222 584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60: 4819-24
24. Sleeman JP, Kim U, LePendu J, Howells N, Coquerelle T, Ponta H et al. Inhibition of MT-450 rat mammary tumour growth by antibodies-recognising subtypes of blood group antigen B. Oncogene 1999; 8: 4485-94
25. Averbeck M, Braun T, Pfeifer G, Sleeman JP, Dudda J, Martin SF et al. Early cytoskeletal rearrangement during dendritic cell maturation enhances synapse formation and Ca(2+) signaling in CD8(+) T cells. Eur J Immunol 2004; 34: 2708-19
26. Schempp CM, Simon-Haarhaus B, Termeer CC, Simon JC. Hypericin photo-induced apoptosis of Jurkat cells involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8. FEBS Lett 2001; 493: 26-30
27. Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19
28. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185-91
29. Nör JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154: 375-84
30. del Valle-Perez B, Martinez-Estrada OM, Vilaro S, Ventura F, Vinals F. cAMP inhibits TGFbeta1-induced in vitro angiogenesis. FEBS Lett 2004; 569: 105-11
31. Ogawa H, Rafiee P, Fisher PJ, Johnson NA, Otterson MF, Binion DG. Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition. FEBS Lett 2003; 554: 88-94
32. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35